1105 related articles for article (PubMed ID: 10327059)
1. Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
Butz K; Whitaker N; Denk C; Ullmann A; Geisen C; Hoppe-Seyler F
Oncogene; 1999 Apr; 18(14):2381-6. PubMed ID: 10327059
[TBL] [Abstract][Full Text] [Related]
2. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells.
Hu G; Liu W; Hanania EG; Fu S; Wang T; Deisseroth AB
Cancer Gene Ther; 1995 Mar; 2(1):19-32. PubMed ID: 7621252
[TBL] [Abstract][Full Text] [Related]
3. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
4. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.
López-Ocejo O; Viloria-Petit A; Bequet-Romero M; Mukhopadhyay D; Rak J; Kerbel RS
Oncogene; 2000 Sep; 19(40):4611-20. PubMed ID: 11030150
[TBL] [Abstract][Full Text] [Related]
5. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.
Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297
[TBL] [Abstract][Full Text] [Related]
6. Effect of UV-irradiation on cell cycle, viability and the expression of p53, gadd153 and gadd45 genes in normal and HPV-immortalized human oral keratinocytes.
Gujuluva CN; Baek JH; Shin KH; Cherrick HM; Park NH
Oncogene; 1994 Jul; 9(7):1819-27. PubMed ID: 8208528
[TBL] [Abstract][Full Text] [Related]
7. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene.
Spitkovsky D; Aengeneyndt F; Braspenning J; von Knebel Doeberitz M
Oncogene; 1996 Sep; 13(5):1027-35. PubMed ID: 8806692
[TBL] [Abstract][Full Text] [Related]
8. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference.
Jiang M; Milner J
Oncogene; 2002 Sep; 21(39):6041-8. PubMed ID: 12203116
[TBL] [Abstract][Full Text] [Related]
9. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells.
Sima N; Wang S; Wang W; Kong D; Xu Q; Tian X; Luo A; Zhou J; Xu G; Meng L; Lu Y; Ma D
Gynecol Oncol; 2007 Aug; 106(2):299-304. PubMed ID: 17586029
[TBL] [Abstract][Full Text] [Related]
10. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells.
Rampias T; Sasaki C; Weinberger P; Psyrri A
J Natl Cancer Inst; 2009 Mar; 101(6):412-23. PubMed ID: 19276448
[TBL] [Abstract][Full Text] [Related]
11. The role of HPV oncoproteins and cellular factors in maintenance of hTERT expression in cervical carcinoma cells.
Jeong Seo E; Jung Kim H; Jae Lee C; Tae Kang H; Seong Hwang E
Gynecol Oncol; 2004 Jul; 94(1):40-7. PubMed ID: 15262117
[TBL] [Abstract][Full Text] [Related]
12. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro.
Slebos RJ; Kessis TD; Chen AW; Han SM; Hedrick L; Cho KR
Virology; 1995 Apr; 208(1):111-20. PubMed ID: 11831691
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells.
Rincon-Orozco B; Halec G; Rosenberger S; Muschik D; Nindl I; Bachmann A; Ritter TM; Dondog B; Ly R; Bosch FX; Zawatzky R; Rösl F
Cancer Res; 2009 Nov; 69(22):8718-25. PubMed ID: 19887612
[TBL] [Abstract][Full Text] [Related]
14. The early HPV16 proteins can regulate mRNA levels of cell cycle genes in human cervical carcinoma cells by p53-independent mechanisms.
Fogel S; Riou G
Virology; 1998 Apr; 244(1):97-107. PubMed ID: 9581783
[TBL] [Abstract][Full Text] [Related]
15. Effect of BPV1 E2-mediated inhibition of E6/E7 expression in HPV16-positive cervical carcinoma cells.
Moon MS; Lee CJ; Um SJ; Park JS; Yang JM; Hwang ES
Gynecol Oncol; 2001 Feb; 80(2):168-75. PubMed ID: 11161855
[TBL] [Abstract][Full Text] [Related]
16. Functional p53 protein in human papillomavirus-positive cancer cells.
Butz K; Shahabeddin L; Geisen C; Spitkovsky D; Ullmann A; Hoppe-Seyler F
Oncogene; 1995 Mar; 10(5):927-36. PubMed ID: 7898934
[TBL] [Abstract][Full Text] [Related]
17. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin.
Putral LN; Bywater MJ; Gu W; Saunders NA; Gabrielli BG; Leggatt GR; McMillan NA
Mol Pharmacol; 2005 Nov; 68(5):1311-9. PubMed ID: 16120770
[TBL] [Abstract][Full Text] [Related]
18. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53.
Sima N; Wang W; Kong D; Deng D; Xu Q; Zhou J; Xu G; Meng L; Lu Y; Wang S; Ma D
Apoptosis; 2008 Feb; 13(2):273-81. PubMed ID: 18060502
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
Mantovani F; Banks L
Oncogene; 1999 Jun; 18(22):3309-15. PubMed ID: 10362351
[TBL] [Abstract][Full Text] [Related]
20. Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses.
Howley PM; Münger K; Romanczuk H; Scheffner M; Huibregtse JM
Princess Takamatsu Symp; 1991; 22():239-48. PubMed ID: 1668886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
